A 62-year-old man with RA for ≥10 years who presented with abdominal bloating was hospitalized. He was receiving MTX (10 mg/week), iguratimod and bucillamine, and he showed no evidence of viral hepatitis, diabetes mellitus or alcoholism. His aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were 79 and 53 U/l, respectively. His platelet count was 50×10^3^/µl. The fibrosis 4 (FIB-4) score, {\[Age (year) x AST (U/l)\] / (platelet (x10^3^/µl) x √ALT (U/l))}, was 13.46 (advanced liver fibrosis). CT performed every few years before hospitalization showed gradually progressing liver atrophy ([Fig. 1a and b](#rkaa014-F1){ref-type="fig"}: 7 and 3 years before hospitalization, respectively). CT performed at the time of hospitalization showed severe liver atrophy and ascites ([Fig. 1c](#rkaa014-F1){ref-type="fig"}). Then, MTX treatment was discontinuated. Ten months after drug discontinuation, his AST and ALT levels reduced to 25 and 20 U/l, respectively, and the platelet count and FIB-4 score were 109×10^3^/µl and 3.23 (moderate liver fibrosis), respectively. The ascites disappeared, and the liver atrophy slowly improved ([Fig. 1d](#rkaa014-F1){ref-type="fig"}).

![CT scan of a patient with MTX-associated reversible liver atrophy in a patient with RA\
(**a**) Seven years before hospitalization. (**b**) Three years before hospitalization. (**c**) At the time of hospitalization. (**d**) Ten months after MTX discontinuation.](rkaa014f1){#rkaa014-F1}

Among all types of MTX-induced liver damage, liver cirrhosis is rare \[[@rkaa014-B1]\]. To our knowledge, there are no reports of radiological changes in the liver and ascites in RA patients receiving MTX \[[@rkaa014-B2]\]. Weekly MTX might induce reversible chronic hepatotoxicity; therefore, in cases of liver atrophy, physicians should discontinue MTX and monitor patients using CT.
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